blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3432877

EP3432877 - D-ALPHA-METHYLDOPA FOR TREATING AUTOIMMUNE DISEASE [Right-click to bookmark this link]
Former [2019/05]METHODS OF TREATING AUTOIMMUNE DISEASE
[2022/32]
StatusNo opposition filed within time limit
Status updated on  17.11.2023
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  09.12.2022
FormerGrant of patent is intended
Status updated on  25.07.2022
FormerExamination is in progress
Status updated on  14.12.2019
FormerRequest for examination was made
Status updated on  30.12.2018
FormerThe international publication has been made
Status updated on  29.09.2017
Formerunknown
Status updated on  18.04.2017
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
ImmunoMolecular Therapeutics, Inc.
299 Washington Street, Suite A
Woburn, MA 01801 / US
For all designated states
The Regents of the University of Colorado, a body corporate
1800 Grant Street, 8th Floor
Denver, CO 80203 / US
[2023/02]
Former [2021/03]For all designated states
ImmunoMolecular Therapeutics, Inc.
3513 S. Brighton Blvd., Suite 431
Denver, CO 80216 / US
For all designated states
The Regents of the University of Colorado, a body corporate
1800 Grant Street, 8th Floor
Denver, CO 80203 / US
Former [2019/41]For all designated states
ImmunoMolecular Therapeutics, LLC
3513 S. Brighton Blvd., Suite 431
Denver, CO 80216 / US
For all designated states
The Regents of the University of Colorado, a body corporate
1800 Grant Street, 8th Floor
Denver, CO 80203 / US
Former [2019/05]For all designated states
IM Therapeutics
11001 West 120th Avenue
Suite 400
Broomfield, CO 80023 / US
For all designated states
The Regents of the University of Colorado, a body corporate
1800 Grant Street, 8th Floor
Denver, CO 80203 / US
Inventor(s)01 / GOTTLIEB, Peter, A.
5413 S. Geneva Way
Englewood, CO 80111 / US
02 / MICHELS, Aaron
14935 East Wagontrial Drive
Aurora, CO 80015 / US
03 / ORNDORFF, Steve
4580 Augusta Drive
Broomfield, CO 80023 / US
 [2019/05]
Representative(s)Witthoff Jaekel Steinecke Patentanwälte PartG mbB
Postfach 1140
52412 Jülich / DE
[2023/02]
Former [2019/05]Steinecke, Peter
Müller Fottner Steinecke
Rechtsanwalts- und Patentanwaltspartnerschaft mbB
P.O. Box 1140
52412 Jülich / DE
Application number, filing date17715858.122.03.2017
[2019/05]
WO2017US23571
Priority number, dateUS201662312702P24.03.2016         Original published format: US 201662312702 P
[2019/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017165508
Date:28.09.2017
Language:EN
[2017/39]
Type: A1 Application with search report 
No.:EP3432877
Date:30.01.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 28.09.2017 takes the place of the publication of the European patent application.
[2019/05]
Type: B1 Patent specification 
No.:EP3432877
Date:11.01.2023
Language:EN
[2023/02]
Search report(s)International search report - published on:EP28.09.2017
ClassificationIPC:A61K31/198, A61K45/06, A61K38/28, A61P3/10, A61P37/00
[2019/05]
CPC:
A61K31/198 (EP,US); A61K38/28 (EP,US); A61K45/06 (EP,US);
A61K9/0053 (US); A61P3/10 (EP); A61P37/00 (EP);
G01N33/564 (US); G01N2800/042 (US) (-)
C-Set:
A61K31/198, A61K2300/00 (EP,US);
A61K38/28, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/05]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:D-ALPHA-METHYLDOPA ZUR BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN[2022/32]
English:D-ALPHA-METHYLDOPA FOR TREATING AUTOIMMUNE DISEASE[2022/32]
French:D-ALPHA-MÉTHYLDOPA POUR LE TRAITEMENT DE MALADIE AUTO-IMMUNE[2022/32]
Former [2019/05]VERFAHREN ZUR BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN
Former [2019/05]METHODS OF TREATING AUTOIMMUNE DISEASE
Former [2019/05]MÉTHODES DE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE
Entry into regional phase17.10.2018National basic fee paid 
17.10.2018Designation fee(s) paid 
17.10.2018Examination fee paid 
Examination procedure17.10.2018Examination requested  [2019/05]
17.10.2018Date on which the examining division has become responsible
10.05.2019Amendment by applicant (claims and/or description)
18.12.2019Despatch of a communication from the examining division (Time limit: M04)
24.04.2020Reply to a communication from the examining division
27.07.2020Despatch of a communication from the examining division (Time limit: M04)
04.12.2020Reply to a communication from the examining division
26.07.2022Communication of intention to grant the patent
02.12.2022Fee for grant paid
02.12.2022Fee for publishing/printing paid
02.12.2022Receipt of the translation of the claim(s)
Opposition(s)12.10.2023No opposition filed within time limit [2023/51]
Fees paidRenewal fee
28.03.2019Renewal fee patent year 03
12.03.2020Renewal fee patent year 04
12.03.2021Renewal fee patent year 05
16.02.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT11.01.2023
CZ11.01.2023
DK11.01.2023
EE11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
IT11.01.2023
LT11.01.2023
LV11.01.2023
MC11.01.2023
NL11.01.2023
PL11.01.2023
RO11.01.2023
RS11.01.2023
SE11.01.2023
SI11.01.2023
SK11.01.2023
SM11.01.2023
IE22.03.2023
LU22.03.2023
BE31.03.2023
CH31.03.2023
LI31.03.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
[2024/26]
Former [2024/11]AT11.01.2023
CZ11.01.2023
DK11.01.2023
EE11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
MC11.01.2023
NL11.01.2023
PL11.01.2023
RO11.01.2023
RS11.01.2023
SE11.01.2023
SI11.01.2023
SK11.01.2023
SM11.01.2023
IE22.03.2023
LU22.03.2023
BE31.03.2023
CH31.03.2023
LI31.03.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
Former [2024/09]AT11.01.2023
CZ11.01.2023
DK11.01.2023
EE11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
MC11.01.2023
NL11.01.2023
PL11.01.2023
RO11.01.2023
RS11.01.2023
SE11.01.2023
SK11.01.2023
SM11.01.2023
IE22.03.2023
LU22.03.2023
CH31.03.2023
LI31.03.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
Former [2024/08]AT11.01.2023
CZ11.01.2023
DK11.01.2023
EE11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
MC11.01.2023
NL11.01.2023
PL11.01.2023
RO11.01.2023
RS11.01.2023
SE11.01.2023
SK11.01.2023
SM11.01.2023
IE22.03.2023
LU22.03.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
Former [2024/02]AT11.01.2023
CZ11.01.2023
DK11.01.2023
EE11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
MC11.01.2023
NL11.01.2023
PL11.01.2023
RO11.01.2023
RS11.01.2023
SE11.01.2023
SK11.01.2023
SM11.01.2023
LU22.03.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
Former [2023/50]AT11.01.2023
CZ11.01.2023
DK11.01.2023
EE11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
MC11.01.2023
NL11.01.2023
PL11.01.2023
RO11.01.2023
RS11.01.2023
SE11.01.2023
SK11.01.2023
SM11.01.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
Former [2023/49]AT11.01.2023
CZ11.01.2023
DK11.01.2023
EE11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
MC11.01.2023
NL11.01.2023
PL11.01.2023
RO11.01.2023
RS11.01.2023
SE11.01.2023
SM11.01.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
Former [2023/48]AT11.01.2023
DK11.01.2023
EE11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
MC11.01.2023
NL11.01.2023
PL11.01.2023
RS11.01.2023
SE11.01.2023
SM11.01.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
Former [2023/46]AT11.01.2023
DK11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
NL11.01.2023
PL11.01.2023
RS11.01.2023
SE11.01.2023
SM11.01.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
Former [2023/39]AT11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
NL11.01.2023
PL11.01.2023
RS11.01.2023
SE11.01.2023
NO11.04.2023
GR12.04.2023
IS11.05.2023
PT11.05.2023
Former [2023/38]AT11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
NL11.01.2023
PL11.01.2023
RS11.01.2023
SE11.01.2023
NO11.04.2023
GR12.04.2023
PT11.05.2023
Former [2023/37]AT11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
NL11.01.2023
RS11.01.2023
SE11.01.2023
NO11.04.2023
GR12.04.2023
PT11.05.2023
Former [2023/36]AT11.01.2023
ES11.01.2023
FI11.01.2023
HR11.01.2023
LT11.01.2023
LV11.01.2023
NL11.01.2023
RS11.01.2023
SE11.01.2023
NO11.04.2023
PT11.05.2023
Former [2023/35]AT11.01.2023
ES11.01.2023
HR11.01.2023
LT11.01.2023
NL11.01.2023
RS11.01.2023
NO11.04.2023
PT11.05.2023
Former [2023/34]ES11.01.2023
LT11.01.2023
NL11.01.2023
RS11.01.2023
PT11.05.2023
Former [2023/33]ES11.01.2023
LT11.01.2023
NL11.01.2023
Former [2023/31]NL11.01.2023
Cited inInternational search[A]WO2005085323  (PEPTIMMUNE INC [US], et al) [A] 1-33 * claims 1,13,18,19,40,46-57,90 *;
 [A]WO2012162697  (UNIV COLORADO REGENTS [US], et al) [A] 1-33 * the whole document *;
 [XP]WO2016191634  (UNIV COLORADO REGENTS [US], et al) [XP] 1-33* page 10, lines 4-19; figures 1-4; claims 1-35 *;
 [X]  - AMES M M ET AL, "Stereochemical course in vivo of alpha-methyldopa decarboxylation in rat brains", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 26, no. 19, doi:10.1016/0006-2952(77)90342-2, ISSN 0006-2952, (19771001), pages 1757 - 1762, (19771001), XP023728982 [X] 24-27 * abstract * * page 1757, column r, paragraph 1 * * page 1758, column r, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/0006-2952(77)90342-2
 [X]  - A. SJOERDSMA ET AL, "Studies on the Metabolism and Mechanism of Action of Methyldopa", CIRCULATION, US, (19631001), vol. 28, no. 4, doi:10.1161/01.CIR.28.4.492, ISSN 0009-7322, pages 492 - 502, XP055379684 [X] 24-27 * page 492, column l, paragraph 1 * * page 492, column r, paragraph 2 * * page 493, column l, paragraph 2 * * table 3 *

DOI:   http://dx.doi.org/10.1161/01.CIR.28.4.492
 [A]  - AG RENWICK ET AL, "The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY., GB, (19830701), vol. 16, no. 1, doi:10.1111/j.1365-2125.1983.tb02147.x, ISSN 0306-5251, pages 77 - 83, XP055379184 [A] 1-33 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1365-2125.1983.tb02147.x
by applicantWO9401775
 WO9429696
 US5415994
 US5424193
 US6001567
 WO9967641
 US2011245334
    - GILLESPIE ET AL., "Clinical and Chemical Studies with a-Methyl-Dopa in Patients with Hypertension", CIRCULATION, (1962), vol. 25, doi:doi:10.1161/01.CIR.25.2.281, pages 281 - 291, XP055379679

DOI:   http://dx.doi.org/10.1161/01.CIR.25.2.281
    - SJOERDSMA ET AL., "Studies on the Metabolism and Mechanism of Action of Methyldopa", CIRCULATION, (1963), vol. 28, doi:doi:10.1161/01.CIR.28.4.492, pages 492 - 502, XP055379684

DOI:   http://dx.doi.org/10.1161/01.CIR.28.4.492
    - AU ET AL., "The Metabolism of C-Labelled ?-Methyldopa in Normal and Hypertensive Human Subjects", BIOCHEM. J., (1972), vol. 129, pages 1 - 10
    - RENWICK ET AL., "The Absorption and Conjugation of Methyldopa in Patients with Coeliac and Crohn's Diseases During Treatment", BR. J. CLIN. PHARMAC., (1983), vol. 16, doi:doi:10.1111/j.1365-2125.1983.tb02147.x, pages 77 - 83, XP055379184

DOI:   http://dx.doi.org/10.1111/j.1365-2125.1983.tb02147.x
    - Optical Resolution Procedures for Chemical Compounds, OPTICAL RESOLUTION INFORMATION CENTER
    - MARTENS, J. ET AL., "Resolution of Optical Isomers by Thin-Layer Chromatography: Enantiomeric Purity of Methyldopa", ARCH. PHARM. (WEINHEIM, (1986), vol. 319, pages 572 - 74
    - GELBER, L.R.; NEUMEYER, J.L., "Determination of the Enantiomeric Purity of Levodopa, Methyldopa, Carbidopa and Tryptophan by the Use of Chiral Mobile Phase High-Performance Liquid Chromatography", J. CHROMATOGRAPHY, (1983), vol. 257, pages 317 - 26, XP026787351
    - OLIVIER, M., "The Invader assay for SNP Genotyping", MUTAT. RES., (20050603), vol. 573, no. 1-2, pages 103 - 110
    - "PCR Protocols: A Guide to Methods and Applications and Bustin SA 2000", INNIS M A ET AL., Journal of Molecular Endocrinology, ACADEMIC PRESS, (1990), pages 169 - 193
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.